New Hope for Diagnosis and Treatment of Intractable Pediatric Brain Tumors

Primitive neuroectodermal tumors (PNETs) arise from undifferentiated brain cells and are the most frequent malignant brain tumors in children. There are different forms of PNETs and, while scientists have made progress in characterizing the genetic abnormalities associated with some PNET subtypes, the highly aggressive cerebral tumors known as CNS-PNETs have been difficult to characterize as they represent a relatively uncommon group of tumors with ill-defined diagnostic features.

“Lack of insight into the molecular pathogenesis of CNS-PNET is a major obstacle towards development of disease-specific models and treatments for these frequently fatal malignancies,” explains senior study author, Dr. Annie Huang from the Hospital for Sick Children in Ontario, Canada. To comprehensively define relevant genetic alterations associated with CNS-PNET, Dr. Huang established international collaborations with colleagues from pediatric oncology centers in Asia, Europe and the United States to complete a sophisticated high resolution genomic screen of a large collection of primary tumors.

» Read more: New Hope for Diagnosis and Treatment of Intractable Pediatric Brain Tumors

Related posts

WATCH: FDA Considers New Cancer Vaccine

WATCH: FDA Considers New Cancer Vaccine
Dr. Richard Besser discusses the possible approval of a prostate cancer vaccine. Cancer – Food and Drug Administration – Health – Conditions and Diseases – Genitourinary

Read more on ABC News

Related posts

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous …

Read more on News-Medical-Net

Related posts